An observational study in Blood Coagulation Disorders, Inherited and Thrombotic Disorder, sponsored by The University of Texas Health Science Center, Houston. Recruiting at 2 sites in United States. Open to participants aged 1 Day to 98 Years. Per ClinicalTrials.gov, last updated 2025-01-09.
Sponsored by The University of Texas Health Science Center, Houston · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 14 studies in Blood Coagulation Disorders, Inherited with a site in United States — 3 open to participants now, 3 under way, 1 of them phase 3. Blood Coagulation Disorders, Inherited · United States.
Among the 14 studies in Blood Coagulation Disorders, Inherited with a site in United States, this one is the only one that started in 2002, is one of 4 observational ones, and was the 1st registered.
21 studies on the registry are indexed under Blood Coagulation Disorders, Inherited; 4 are open to participants now.
Browse Blood Coagulation Disorders, Inherited studies →3 of the 14 studies in Blood Coagulation Disorders, Inherited with a site in United States are open now. Recruiting first, the newest first:
Hemab ApS · Sites in United States
Ages 12–70
BioMarin Pharmaceutical · Sites in United States, Australia, Belgium and 9 more countries
Ages 18+ · Men only
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 2 Blood Coagulation Disorders, Inherited studies recruiting now, none set no upper age limit and 1 stops at 75 or younger; 2 take children under 18; none take healthy volunteers.
This study: 1 Day to 98 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
14 studies; the count open now beside each. This study's row is marked.
First in 2002; this study’s year is marked. 1 started in 2002.
Median enrollment 24 across the 10 interventional studies, 105 across the 4 observational. Of the 10 that completed or were terminated, 7 (70%) have results posted.
This tab as a report to print or save as PDF → With an account.
13 of 14 have an industry lead sponsor. The 7 most frequent:
The University of Texas Health Science Center, Houston is the lead sponsor of 899 studies on the registry; 214 are open to participants now.
Of its 174 completed or terminated interventional studies of FDA-regulated products, 142 (82%) have results posted.
The University of Texas Health Science Center, Houston has 1 study filed under Blood Coagulation Disorders, Inherited — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 14 studies in Blood Coagulation Disorders, Inherited with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The objective of this study will be to assess the coagulation system in-vitro in a variety of bleeding and clotting disorders using the ROTEG analyzer and the thrombin generation assay.
This is an exploratory study involving blood coagulation assays in a select group of individuals receiving treatment for their congenital or acquired bleeding or clotting disorder at UTHealth Houston. The ROTEG is a newly developed coagulation analyzer which allows the continuous assessment of whole blood coagulation from the formation of the first fibrin fibers and activated platelets, to the formation of a three-dimensional whole blood clot until the eventual dissolution of the clot. This device will not be used as a diagnostic or procedure tool. No recommendations regarding interpretation of the results or implications for future treatment will be provided.
Subjects with an acquired or congenital bleeding disorder or acquired thrombotic disorder receiving treatment for their condition at UTHealth Houston.
Inclusion Criteria: patients with congenital or acquired bleeding or clotting disorders who have provided and/or assent
Exclusion Criteria: poor venous access
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Assess primary and secondary hemostasis in individuals with bleeding and clotting disorders
Coagulation will be assessed by continuously recording clot firmness, thrombin generation, and platelet function
Time frame: 24 hours
Plan to share: Undecided — Undecided at this time
No publications or documents are linked to this record.
Started Oct 2002 (actual). Primary completion is estimated for Jan 2028, 303 months after the start.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Blood Coagulation Disorders, Inherited →
The University of Texas Health Science Center, Houston →